Indigo Diabetes Business Update – GlobeNewswire
PRESS RELEASE
Indigo Diabetes Business Update
BELGIUM – Ghent, December 21, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.
Clinical study progressThe GLOW study, which was initiated in March 2021 and is the first in human clinical study of its continuous multi-metabolit…….
PRESS RELEASE
Indigo Diabetes Business Update
BELGIUM – Ghent, December 21, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.
Clinical study progress
The GLOW study, which was initiated in March 2021 and is the first in human clinical study of its continuous multi-metabolite (‘CMM’) sensor, was recently completed. GLOW, listed on www.clinicaltrials.gov under the identifier NCT04782934, was designed to evaluate the safety of the sensor and the short-term integration into the tissue and was a prospective, single-center early feasibility study conducted at Antwerp University Hospital, Belgium. Data was also collected from the seven study participants and used to develop the device to allow real-time, continuous measurement of key metabolite levels in adults with diabetes. The GLOW study results are currently being analysed and due to be submitted for publication in the New Year.
Key appointments
In May, Indigo appointed Paul Moraviec as Chairman of its Board of Directors. Paul has amassed over three decades of global experience in the healthcare sector, having held multiple senior leadership positions and has brought highly relevant diabetes experience, having been Vice President of Abbott’s Diabetes Care International division between 2002 and 2007.
In addition, Indigo appointed seven internationally recognised experts in endocrinology, diabetes and metabolic disease to form its newly created Scientific Advisory Board (SAB). The SAB members are all leaders in their field and will serve as a strategic resource to Indigo as it progresses its device and continues its journey to transforming diabetes management. The SAB, which held its first meeting in June 2021, comprises:
- Prof. Dr. Tadej Battelino, Head of Department of Endocrinology, Diabetes & Metabolism, Faculty of Medicine, University of Ljubljana, Slovenia
- Prof. Dr. Michael C. Riddell, School of Kinesiology & Health Science, York University, Canada
- Prof. Dr. Eric Renard, Head of Department Endocrinology, Diabetes & Metabolism, Medical School, University of Montpellier, France
- Prof. Dr. Christophe De Block, Head of Department of Endocrinology, Diabetology and Metabolic disease, University of Antwerp, Belgium
- Prof. Dr. Thomas Danne, Director of Department of General Pediatrics Endocrinology/Diabetology & Clinical Research, Hannover Medical School, Germany
- Prof. Dr. Ananda Basu, Division of Endocrinology, University of Virginia, USA
- Dr. Anne Peters, Keck School of Medicine, University of Southern California, USA
In December 2021, Indigo appointed Daniel Verstappen as VP Quality Assurance and Regulatory Affairs where he will form part of the senior management …….
